Objective:To investigate the feasibility and safety of endoscopic surgery for the treatment of primary hyperthyroidism with goiter.Methods:A total of 140 patients with primary hyperthyroidism and different degrees of thyroid enlargements were included who underwent endoscopic surgeries via a trans breast approach in the Second Affiliated Hospital of Zhejiang University School of Medicine from 2013 to 2023, including 137 females and 3 males, aged from 16 to 49 years old. Thirty-one cases had normal thyroid size, 25 cases had Grade Ⅰ enlargement, 56 cases had Grade Ⅱ enlargement, and 28 cases had Grade Ⅲ enlargement. Demographic characteristics, operative time, intraoperative blood loss, and postoperative complications were described, analyzed, and compared among groups. Student′s t-test, Mann-Whitney U test, chi-square test, Fisher exact test or one-way analysis of variance (ANOVA) were used for statistical analyses. Results:The patients with Grade Ⅲ enlargement were younger compared to other groups ( F=5.58, P<0.01), and also had significantly longer operative time ( F=2.81, P=0.04). The probability of conversion to open surgery in the Grade Ⅲ enlargement group was 10.7% (3/28), significantly higher than other groups (0/31, 0/25, 1/56, χ2=8.11, P=0.04). There were no significant differences among the four groups in terms of other demographic indicators and the incidences of postoperative complications (including recurrent laryngeal nerve injury, hypocalcemia, and surgical site infection). There was no significant difference in the probability of temporary hypoparathyroidism among the 4 groups. One patient with permanent hypoparathyroidism appeared respectively in the normal size group and Grade Ⅱ enlargement group. The average follow-up time was 4.2±3.7 years and 14 cases were lost to follow-up, and the patients had high satisfaction with"no neck scar"but with mild chest discomfort. Conclusion:The risk of endoscopic thyroid surgery in the treatment of primary hyperthyroidism with goiter is controllable, and patients with hyperthyroidism combined with Grade Ⅲ enlargement should be especially vigilant against the risk of conversion to open surgery.

Objective:To investigate the feasibility and safety of endoscopic surgery for the treatment of primary hyperthyroidism with goiter.Methods:A total of 140 patients with primary hyperthyroidism and different degrees of thyroid enlargements were included who underwent endoscopic surgeries via a trans breast approach in the Second Affiliated Hospital of Zhejiang University School of Medicine from 2013 to 2023, including 137 females and 3 males, aged from 16 to 49 years old. Thirty-one cases had normal thyroid size, 25 cases had Grade Ⅰ enlargement, 56 cases had Grade Ⅱ enlargement, and 28 cases had Grade Ⅲ enlargement. Demographic characteristics, operative time, intraoperative blood loss, and postoperative complications were described, analyzed, and compared among groups. Student′s t-test, Mann-Whitney U test, chi-square test, Fisher exact test or one-way analysis of variance (ANOVA) were used for statistical analyses. Results:The patients with Grade Ⅲ enlargement were younger compared to other groups ( F=5.58, P<0.01), and also had significantly longer operative time ( F=2.81, P=0.04). The probability of conversion to open surgery in the Grade Ⅲ enlargement group was 10.7% (3/28), significantly higher than other groups (0/31, 0/25, 1/56, χ2=8.11, P=0.04). There were no significant differences among the four groups in terms of other demographic indicators and the incidences of postoperative complications (including recurrent laryngeal nerve injury, hypocalcemia, and surgical site infection). There was no significant difference in the probability of temporary hypoparathyroidism among the 4 groups. One patient with permanent hypoparathyroidism appeared respectively in the normal size group and Grade Ⅱ enlargement group. The average follow-up time was 4.2±3.7 years and 14 cases were lost to follow-up, and the patients had high satisfaction with"no neck scar"but with mild chest discomfort. Conclusion:The risk of endoscopic thyroid surgery in the treatment of primary hyperthyroidism with goiter is controllable, and patients with hyperthyroidism combined with Grade Ⅲ enlargement should be especially vigilant against the risk of conversion to open surgery.

Objective:To explore and analyze the value of CT texture combined with baseline data in lymph node metastasis of cN0 papillary thyroid microcarcinoma (PTMC), in order to provide evidence for the evaluation of lymph node metastasis of PTMC.Methods:106 patients with single stage cN0 papillary PTMC confirmed by operation and pathology in Department of Radiology and Hernia Department of Huzhou First People’s Hospital from Aug. 2020 to Aug. 2022 were selected for retrospective analysis. Metastatic lymph nodes and non-metastatic lymph nodes were delineated in CT images, and they were divided into a lymph node metastasis group (22 cases) and a group without lymph node metastasis (84 cases). At the same time, lymph node CT texture feature images were obtained in both groups. Logistic regression was used to analyze the relationship between CT texture and lymph node metastasis, and ROC curve was drawn to evaluate the predictive value of CT texture for lymph node metastasis in cN0 stage PTMC patients. The patients were divided into<1/4 group (51 cases), 1/4-<1/2 group (36 cases), and ≥1/2 group (19 cases) according to the different contact range between tumor and thyroid margin in CT signs. The baseline data and lymph metastasis distribution of each group were analyzed.Results:The results of single factor analysis showed that there were no differences in tumor location, tumor calcification or thyroglobulin in CT texture between LNM group and non-LNM group ( P>0.05). The incidence of tumor contact with thyroid margin, tumor diameter ≥7 mm, age<45 and male ratio of sex in LNM group were higher than those in non-LNM group ( P<0.05). Multivariate Logistic regression analysis showed that tumor was in contact with thyroid margin ( OR=6.080, 95% CI: 1.738-21.273), tumor diameter ≥7 mm ( OR=2.779, 95% CI: 1.135-6.805), age<45 years old ( OR=6.074, 95%CI: 1.980-18.636) and gender male ( OR=12.642, 95% CI: 3.125-51.136) were independent risk factors for lymph node metastasis in cN0 stage PTMC patients ( P<0.05). There were no significant differences in gender, age, tumor diameter, tumor location, tumor calcification or thyroglobulin among<1/4 group, 1/4-1/2 group and ≥1/2 group ( P>0.05). The incidence of LNM in ≥1/2 group was higher than that in<1/4 group and 1/4-1/2 group, and pairwise comparison between groups had statistical significance ( P<0.05) . Conclusions:It is an independent risk factor for lymph node metastasis in cN0 stage PTMC patients with tumor and thyroid boundary contact, tumor diameter ≥7 mm, age<45 years old, male, and the wider the tumor and thyroid boundary contact, the higher the risk of lymph node metastasis. CT texture analysis combined with baseline data has important reference value in predicting lymph node metastasis of cN0 TMPC.

Objective To analyze the outcome and the prognostic factors of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). Methods A total of 797 patients receiving HSCT were analyzed retrospectively. The prophylaxis regimen of HVOD in the First Affiliated Hospital of Guangxi Medical University consisted of low molecular weight heparin and lipoprostaglandin E1 (PGE1). Results Fifty-nine patients (7.4%) developed HVOD at 3-49 days after HSCT (median 12 days). Age younger than 15 years at transplant( HR=6.47, P<0.001), busulphan conditioning ( HR=6.40, P<0.001), thalassemia major ( HR=6.35,P<0.001), allogeneic transplantation ( HR=7.74, P=0.005) were univariate risk factors for HVOD. Multivariate analyses suggested that thalassemia major and busulphan conditioning were independently correlated with the development of HVOD. Conclusion Thalassemia major and busulphan conditioning are independent risk factors for HVOD after HSCT.

Objective To evaluate the effects of preoperative regional intra-arterial infusion chemotherapy for patients with advanced gastric cancer (AGC). Methods A total of 82 patients with clinical stage Ⅲ,Ⅳ gastric cancer received two cycles of neoadjuvant regional intra-arterial infusion chemotherapy (arterial infusion group, n=42) or neoadjuvant systemic chemotherapy (systemic chemotherapy group, n=40). The operation was administrated in 10 to 15 days before chemotherapy. All patients received 6 course of systemic chemotherapy after surgery. Chemotherapy toxicity and sur-vival rate were retrospectively analyzed. Results No significant difference was found in chemotherapy toxicity between two groups. The median survival period was 25.3 months in arterial infusion group and 19.1 months in systemic chemotherapy group. 3-year survival rate was 36.4% in arterial infusion group and 21.0% in systemic chemotherapy group respectively, there were significant differences (P<0.05). Conclusion Preoperative regional intra-arterial infusion chemotherapy is well tolerated in advanced gastric cancer patients and could improve short-term survival.